|
| August 28, 2019 | |
| |
| The latest antibodies news from News Medical | |
|
|
|
| Using a Bridging Assay for Anti-Drug Antibody Detection
Therapeutic drugs that are based on biological materials, like fusion proteins, enzymes, cytokines, hormones, and antibodies, may have the potential to trigger an immune response in the host. Immunogenicity of a therapeutic can be described as the undesirable stimulation of an immune response by the host to the therapeutic.
| |
|
|
|
|
|
| Antibodies are proteins that can bind to specific molecules called antigens. They have different portions in their Y-shaped structure that can bind to antigens and effector molecules. Several types of antibodies such as primary and secondary and monoclonal and polyclonal antibodies with varying specificities have been developed in recent years. | |
|
| In most clinical applications, the monoclonal antibodies (mAbs) used are usually of murine origin; however, the small spleen of the mouse is limited in its ability to generate antibodies. | |
|
| Research on therapies against the Human Immunodeficiency Virus (HIV) has repeatedly demonstrated the potential of broadly neutralizing antibodies (bn-Abs) as successful therapeutic agents. Injection of such antibodies leads to a decrease in viral concentrations in blood. However, repeated injections are necessary to prevent the recovery of the virus. | |
|
| An antibody that blocks the "programmed cell death" pathway may help the immune system fight off sepsis-related fungal infections, according to animal studies reported in SHOCK: Injury, Inflammation, and Sepsis: Laboratory and Clinical Approaches, Official Journal of the Shock Society. | |
|
|
|
|
No hay comentarios:
Publicar un comentario